{"id":27094,"date":"2026-09-03T15:41:52","date_gmt":"2026-09-03T19:41:52","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=27094"},"modified":"2026-09-03T16:14:31","modified_gmt":"2026-09-03T20:14:31","slug":"new-emilys-entourage-grant-to-fund-novel-phage-based-therapy-for-drug-resistant-infections-in-cystic-fibrosis","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/pt_br\/new-emilys-entourage-grant-to-fund-novel-phage-based-therapy-for-drug-resistant-infections-in-cystic-fibrosis\/","title":{"rendered":"Novo subs\u00eddio da Emily's Entourage para financiar terapia inovadora baseada em fagos para infec\u00e7\u00f5es resistentes a medicamentos na fibrose c\u00edstica"},"content":{"rendered":"

Inhaled bacteriophage-antibiotic combination could offer a new treatment approach for persistent, antibiotic-resistant lung infections<\/span><\/i><\/p>\n

\"\"

Emily’s Entourage (EE) has awarded its fourth 2026 Translational Research Grant to David T. Pride, MD, PhD, Professor of Pathology and Medicine at the University of California San Diego School of Medicine.<\/p><\/div>\n

Lower Merion, PA\u2014September 3, 2026\u2014<\/span>Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating research for individuals with cystic fibrosis (CF) who do not benefit from current mutation-targeted therapies, is proud to announce its fourth<\/span> 2026 Translational Research Grant awarded to David T. Pride, MD, PhD, Professor of Pathology and Medicine at the University of California San Diego School of Medicine.<\/span><\/p>\n

Dr. Pride\u2019s project aims to develop a novel inhaled therapy combining bacteriophages\u2014viruses that specifically target and kill bacteria\u2014with the antibiotic meropenem to treat persistent lung infections in people with CF that are resistant to standard antimicrobial therapies.<\/span><\/p>\n

Chronic infections and the development of antibiotic resistance pose a major threat to people with CF, driving disease progression and mortality. Among the most challenging of these infections is <\/span>Achromobacter xylosoxidans<\/span><\/i>, a pathogen that can persist in the CF lung despite repeated antibiotic treatment and frequently develops multidrug-resistant (MDR) or extensively drug-resistant (XDR) profiles, leaving people with CF with limited therapeutic options.<\/span><\/p>\n

Dr. Pride and his team have identified a large and diverse collection of bacteriophages capable of targeting and killing <\/span>Achromobacter<\/span><\/i>, with activity observed across a wide range of MDR and XDR clinical isolates. Building on this work, they have made a key discovery: when certain phages are combined with the antibiotic meropenem, the two work synergistically to eliminate the bacteria, even in cases where the bacteria are initially resistant to the antibiotic. This finding suggests a new approach to treatment, in which antibiotic effectiveness may be restored through combinations with phage therapy, expanding treatment options for resistant infections.<\/span><\/p>\n

The team will investigate the biological mechanisms underlying this synergy to better understand how and why this approach is effective.<\/span><\/p>\n

\"<\/span>Achromobacter<\/span><\/i> infections are particularly difficult to treat because of their ability to develop and maintain resistance to multiple antibiotics,\u201d said Dr. Pride. \u201cBy combining bacteriophages with existing antibiotics, we have the potential to restore antibiotic activity and provide a new treatment option for people with CF who have exhausted conventional antibiotic therapies.\u201d<\/span><\/p><\/blockquote>\n

Approximately 10% of people with CF do not benefit from current CFTR modulators and often face a disproportionate burden of chronic, treatment-resistant infections. EE is committed to advancing research that addresses both the underlying genetic causes of CF and the serious issues that continue to impact those living with CF.<\/span><\/p>\n

\u201cThis project represents an innovative and urgently needed approach to addressing antibiotic-resistant infections in CF,\u201d said Chandra Ghose, PhD, Chief Scientific Officer at EE. \u201cBy leveraging the unique ability of bacteriophages to target resistant bacteria\u2014and combining them with existing antibiotics to restore their antimicrobial effects\u2014this work has the potential to expand treatment options for individuals facing some of the most difficult-to-treat infections.\u201d<\/span><\/p>\n

 <\/p><\/blockquote>\n

Sobre o programa de subs\u00eddios do Emily's Entourage (EE)<\/b><\/p>\n

O Programa de Subs\u00eddios da Emily\u2019s Entourage (EE) fornece financiamento para acelerar a pesquisa e o desenvolvimento terap\u00eautico para pessoas com fibrose c\u00edstica (FC) que n\u00e3o se beneficiam de terapias existentes direcionadas a muta\u00e7\u00f5es. O EE apoia uma variedade de mecanismos de financiamento, incluindo subs\u00eddios translacionais, subs\u00eddios colaborativos e subs\u00eddios explorat\u00f3rios pr\u00e9-cl\u00ednicos, bem como investimentos de filantropia de risco.<\/span><\/p>\n

At\u00e9 o momento, a EE concedeu milh\u00f5es de d\u00f3lares a equipes multidisciplinares em todo o mundo e ajudou a garantir milh\u00f5es adicionais em financiamento subsequente. Para ver as bolsas concedidas, visite <\/span>https:\/\/www.emilysentourage.org\/awarded-grants\/<\/span><\/a>. Para saber mais sobre as oportunidades de financiamento da EE, acesse <\/span>https:\/\/www.emilysentourage.org\/funding-opportunities\/<\/span><\/a>.<\/span><\/p>\n

Sobre a comitiva de Emily<\/b><\/p>\n

A Emily\u2019s Entourage (EE) \u00e9 uma organiza\u00e7\u00e3o inovadora sem fins lucrativos, registrada como 501(c)3, que acelera a pesquisa de novos tratamentos e de uma cura para indiv\u00edduos na fase final da fibrose c\u00edstica (FC) que n\u00e3o se beneficiam das terapias direcionadas a muta\u00e7\u00f5es dispon\u00edveis atualmente. Desde 2011, a EE j\u00e1 concedeu milh\u00f5es de d\u00f3lares em subs\u00eddios de pesquisa, lan\u00e7ou uma empresa de terapia g\u00eanica para FC em fase cl\u00ednica, desenvolveu o banco de dados de pacientes Clinical Trial Connect (CTC) e o programa de conex\u00e3o com ensaios cl\u00ednicos para acelerar o recrutamento global para esses ensaios, al\u00e9m de liderar esfor\u00e7os mundiais para impulsionar pesquisas de alto impacto e o desenvolvimento de medicamentos. A organiza\u00e7\u00e3o tem sido destaque na m\u00eddia nacional, incluindo o New York Times, STAT, CNN, People e outros. Saiba mais em <\/span>emilysentourage.org<\/span><\/a>.<\/span><\/p>\n

Contato com a m\u00eddia<\/b><\/p>\n

Hannah Kleckner<\/span><\/p>\n

Diretor de Marketing e Comunica\u00e7\u00f5es<\/span><\/p>\n

hannah@emilysentourage.org<\/span><\/p>\n



<\/p>","protected":false},"excerpt":{"rendered":"

Inhaled bacteriophage-antibiotic combination could offer a new treatment approach for persistent, antibiotic-resistant lung infections Lower Merion, PA\u2014September 3, 2026\u2014Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating research for individuals with cystic fibrosis (CF) who do not benefit from current mutation-targeted therapies, is proud to announce its fourth 2026 Translational Research Grant awarded to David T…. <\/p>\n

<\/div>\n

Leia mais<\/a><\/p>","protected":false},"author":1719,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"New Emily\u2019s Entourage Grant to Fund Novel Phage-Based Therapy for Drug-Resistant Infections in Cystic Fibrosis","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[178],"tags":[197,217,223,204,270,189],"class_list":["post-27094","post","type-post","status-publish","format-standard","hentry","category-press-releases","tag-cf-research","tag-cf-science","tag-ee-grant","tag-ee-research","tag-new-cf-research","tag-phage-therapy"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/posts\/27094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/users\/1719"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/comments?post=27094"}],"version-history":[{"count":5,"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/posts\/27094\/revisions"}],"predecessor-version":[{"id":27100,"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/posts\/27094\/revisions\/27100"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/media?parent=27094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/categories?post=27094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt_br\/wp-json\/wp\/v2\/tags?post=27094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}